Cartesian Therapeutics
RNAC
36 hedge funds and large institutions have $32.4M invested in Cartesian Therapeutics in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 16 reducing their positions, and 11 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.18% less ownership
Funds ownership: 1.55% → 1.37% (-0.18%)
13% less capital invested
Capital invested by funds: $37.3M → $32.4M (-$4.87M)
18% less funds holding
Funds holding: 44 → 36 (-8)
56% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 16
73% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$289K |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$45.3K |
| 3 |
HF
HRT Financial
New York
|
+$24K |
| 4 |
Two Sigma Investments
New York
|
+$20.6K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$16.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$977K |
| 2 |
FI
Fosun International
Hong Kong,
China
|
-$824K |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$767K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$532K |
| 5 |
Millennium Management
New York
|
-$256K |
RNAC Hedge Fund Activity: Q3 2019 in Review
36 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q3 2019, worth a combined $32.4M — down 13% from $37.3M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of RNAC and 3 opened new positions — a net loss of 8 holders — while 16 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, adding an estimated $289K. The largest seller was Vivo Capital, exiting entirely with an estimated $977K sold.
- 36 institutional investors held Cartesian Therapeutics (RNAC) as of Q3 2019, down from 44 in Q2 2019.
- Funds reported $32.4M of Cartesian Therapeutics stock for Q3 2019, down 13% quarter-over-quarter.
- 3 funds opened new Cartesian Therapeutics positions in Q3 2019 and 11 closed out, a net change of -8 holders.
- The largest Cartesian Therapeutics buyer in Q3 2019 was Renaissance Technologies, an estimated $289K added.
- The largest Cartesian Therapeutics seller in Q3 2019 was Vivo Capital, an estimated $977K sold.
Based on aggregated 13F filings for Q3 2019.